Therapy in Bronchopulmonary Diseases Associated with Increased Secretion of Viscous Sputum and Impaired Mucus Transport

Article Sidebar

PDF (Українська)
Published: Mar 20, 2015
DOI: https://doi.org/10.22141/2224-0551.1.60.2015.74978
Keywords:
cough, sputum, treatment, ambroxol.

Main Article Content

Yu.V. Marushko
National Medical University named after O.O. Bohomolets, Kyiv
http://orcid.org/0000-0001-8066-9369
M.H. Hrachova
National Medical University named after O.O. Bohomolets, Kyiv

Abstract

The article deals with the problem of cough in bronchopulmonary diseases, in particular, the attention is paid to cough with increased secretion of viscous sputum, i.e., productive cough. It is noticed that derivative of vasicine alkaloid — ambroxol belongs to effective secretolytic mucoactive drugs. A review of researches on ambroxol efficacy in pediatrics is provided, the characteristics of Ambrolitin manufactured by European pharmaceutical company «Sopharma», which active ingredient is ambroxol, are given.

Article Details

How to Cite
Marushko, Y., and M. Hrachova. “Therapy in Bronchopulmonary Diseases Associated With Increased Secretion of Viscous Sputum and Impaired Mucus Transport”. CHILD`S HEALTH, no. 1.60, Mar. 2015, pp. 135-9, doi:10.22141/2224-0551.1.60.2015.74978.
Issue
No. 1.60 (2015)
Section
To Help the Pediatrician
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our edition uses the copyright terms of Creative Commons for open access journals.

Authors, who are published in this journal, agree with the following terms:

  1. The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
  2. Directing  the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
  3. The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
  4. The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
  5. The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
  6. The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
  7. The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal. 

References

Бойцова Е.В. Муколитическая терапия у детей // Медицинский совет. — 2013. — № 1. — С. 58-63.

Ермакова И.Н. Карбоцистеин (Флюдитек) в комплексной терапии рецидивирующих респираторных инфекций нижних дыхательных путей у детей / И.Н. Ермакова, Ю.Л. Мизерницкий // Земский врач. — 2012. — № 5(16). — С. 12-16.

Зайцева О.В. Муколитические препараты в терапии болезней органов дыхания у детей: современный взгляд на проблему // РМЖ. — 2003. — № 1, Т. 11. — С. 49-54.

Зубаренко А.В. Новые подходы в лечении кашля у детей с использованием раствора Флавамед / А.В. Зубаренко, Е.А. Гуриенко, Н.Ю. Горностаева // Здоровье ребенка. — 2011. — № 1(28). — С. 33-36.

Клячкина И.Л. Муколитик амброксол в программе лечения заболеваний нижних дыхательных путей // Consilium Medicum. Справочник поликлинического врача. — 2010. — № 10.

Крамарев С.А. Дифференцированный подход к лечению кашля // Здоровье ребенка. — 2013. — № 6(49). — С. 100-104.

Марушко Ю.В., Крамарьов С.О., Шеф Г.Г. та ін. Захворювання органів дихання в дітей. Невідкладні стани в дитячій пульмонології. — Київ, Харків: Планета-Принт, 2013. — 313 с.

Недельская С.Н. Клиническая эффективность применения препарата Флавамед у детей раннего возраста с патологией респираторной системы / С.Н. Недельская, И.В. Солодова, Л.Н. Боярская и др. // Здоровье ребенка. — 2007. — № 1(4). — С. 34-36.

Оковитый С.В. Фармакологические подходы к противокашлевой терапии / С.В. Оковитый, Н.А. Анисимова // РМЖ. — 2011. — № 23. — С. 1450-1458.

Практическая пульмонология детского возраста: Справочник / Под ред. В.К. Таточенко. — М., 2008.

Харченко Ю.П. Эффективность Флавамеда в лечении ОРВИ у детей // Здоровье ребенка. — 2008. — № 5 (14). — С. 8-12.

Юлиш Е.И. Дифференцированный подход к лечению кашля у детей / Е.И. Юлиш, О.Е. Чернышева, Е.В. Глинская // Здоровье ребенка. — 2013. — № 1 (44). — С. 33-39.

Юлиш Е.И. Дифференцированный подход к проведению муколитической терапии при респираторной патологии у детей // Здоровье ребенка. — 2013. — № 7 (50). — С. 127-133.

Gibbs B.F. Differential modulation of IgE dependent activation of human basophils by ambroxol and related secretolytic analogues // Int. J. Immunopathol. Pharmacol. — 2009, Oct-Dec. — 22 (4). — Р. 919-927.

Kern J.A., Lamb R.J. et al. Dexamethasone inhibition of interleukin 1 beta production by human monocytes. Posttranscriptional mechanisms // J. Clin. Invest. — 1988. — 81. — 237-244.

Kido H., Okumura Y., Yamada H. et al. Secretory leukoprotease inhibitor and pulmonary surfactant serve as principal defenses against influenza A virus infection in the airway and chemical agents upregulating their levels may have therapeutic potential // Biol. Chem. — 2004, Nov. — 385 (11). — Р. 1029-1034.

Principi N., Zavattini G., Daniotti S. Possibility of interaction among antibiotics and mucolytics in children // Int. J. Clin. Pharmacol. Res. — 1986. — Vol. 6, № 5. — Р. 369-372.

Most read articles by the same author(s)

1 2 3 4 > >>